Physician profile
Shabnam Sachdeva
NPI 1598786717
$15,247.16
in general payments reported to CMS, 2019-2025
55 companies · $1,922 in 2025
The $1,922 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,244 · 2020: $2,359 · 2021: $2,048 · 2022: $2,204 · 2023: $1,984 · 2024: $2,485 · 2025: $1,922.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,150 · Education: $223 · Consulting Fee: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,149.54 |
| Education | $222.51 |
| Consulting Fee | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,023.50 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $1,725.96 | 2019-2025 | Repatha, Otezla, Otezla |
| Astrazeneca Pharmaceuticals LP | $1,605.45 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,294.30 | 2019-2025 | Jardiance, Synjardy |
| Abbvie INC. | $1,110.29 | 2019-2025 | Qulipta, Synthroid, Ubrelvy |
| Lilly USA, LLC | $1,055.35 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $693.01 | 2019-2025 | |
| Astellas Pharma US INC | $593.01 | 2019-2025 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $592.42 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Sanofi-Aventis U.S. LLC | $501.79 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $359.95 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $344.91 | 2019-2025 | Xifaxan, Trulance |
| Amarin Pharma, INC. | $336.48 | 2019-2022 | |
| Esperion Therapeutics, INC. | $291.36 | 2020-2025 | Nexletol |
| Merck Sharp & Dohme LLC | $241.33 | 2019-2022 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shabnam Sachdeva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.